MYND Life Sciences Provides Update on Depression Gene Modulation Pathway Patent...

Psychedelics and Substance Use Disorder: 4000 BCE to Present Day

MINDCURE Announces Certification of HIPAA Compliance, Bringing iSTRYM Closer to Commercial...

atai Impact Establishes the atai Fellowship Fund in Psychedelic Neuroscience with...

Psyched Wellness Announces Path to Market for AME-1-derived Products in the...

COMPASS Pathways announces changes in Executive Team

Awakn Life Sciences Reports Fiscal Third Quarter 2021 Financial Results and...

Cybin Awarded Notice of Allowance from U.S. Patent and Trademark Office...

Apeiron and Other Key Shareholders of atai Life Sciences Reinforce Support...

Editor’s Choice Award 2021-Best Study on Psychedelics and Neuroplasticity

Load more